Foghorn Therapeutics Appoints Kristian Humer as New CFO
Company Announcements

Foghorn Therapeutics Appoints Kristian Humer as New CFO

Foghorn Therapeutics (FHTX) has issued an announcement.

Foghorn Therapeutics Inc. has appointed Kristian F. Humer as their new Chief Financial Officer, bringing a wealth of experience from his previous role at Viridian Therapeutics and a strong background in healthcare investment banking with Citi, Lehman Brothers, UBS, and Merrill Lynch. Humer, who also serves on the board of Sensei Biotherapeutics, will receive a competitive compensation package, including a $475,000 base salary, potential for a 40% performance bonus, a $87,000 signing bonus, and an option to purchase 275,000 company shares. His appointment, effective immediately, marks a strategic move for Foghorn as they navigate the financial landscape of the biotechnology sector.

See more insights into FHTX stock on TipRanks’ Stock Analysis page.

Related Articles
Carrie WilliamsFHTX Earnings this Week: How Will it Perform?
TipRanks Auto-Generated NewsdeskFoghorn Therapeutics Unveils Clinical Pipeline Progress
TheFlyFoghorn Therapeutics announces first patient dosed with FHD-909
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App